A Real-world Study of Apatinib in the treatment for Inoperable or advanced gastric cancer in Shandong

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1800015701

Enrollment

Unknown

Registered

2018-04-16

Start date

2018-04-16

Completion date

Unknown

Last updated

2018-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inoperable or advanced gastric cancer

Interventions

Case series:apatinib

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged = 18 years old, male or female; 2. Patients with histopathology and/or cytology confirmed, inoperable or advanced gastric cancer ; 3. The patients are willing to join the study, and sign the informed consent; 4. Patients can benifit from apatinib at the investigator's discretion.

Exclusion criteria

Exclusion criteria: 1. Patients with operable gastric cancer; 2. Allergic to apatinib or its excipients; 3. Pregnant and lactant women; 4. Patients with contraindications for apatinib; 5. The other situation that doctor considered not suitable for enrolling.

Design outcomes

Primary

Measure	Time frame
OS;PFS;DCR;Safety;	—

Countries

China

Contacts

Public ContactJinming Yu

Shandong Cancer Hospital

251400067@qq.com+86 15553181309

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 21, 2026